City Therapeutics Valuation, Funding & Investors

Vedanta Biosciences is a Cambridge, Massachusetts-based biotechnology company engineering microbiome immunotherapies for autoimmune, inflammatory, and infectious diseases. It develops consortia of live bacteria selected via proprietary assays from human donor samples, manufactured in cGMP facilities for oral administration. Vedanta's lead candidate VE202 advances in Phase 2 for graft-versus-host disease, with prior programs partnered to Janssen for Crohn's disease. Founded in 2010 as Seres spin-out, it maintains a library of over 1,000 bacterial strains and datasets from interventional studies.

Inceptive is a biotechnology firm that engineers RNA molecules through deep learning models refined by high-throughput wet-lab experiments. Headquartered in South San Francisco, the company builds platforms for designing mRNA vaccines, gene therapies, and protein therapeutics. Its Evo 2.0 model generates novel RNA sequences with specified properties, accelerating development of treatments for infectious diseases and rare genetic disorders.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Tiansheng Pharmaceutical Group Co Ltd is a pharmaceutical company. It is engaged in the research, development, production, and sales of pharmaceutical products. The company's business scope covers pharmaceutical manufacturing, circulation, Chinese herbal medicine planting and processing, drug research and development, and others. Its products cover respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, oncology, hepatobiliary, blood, surgery, diabetes and other systems.

Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.

AmplifyBio is a Columbus Ohio-headquartered biotechnology firm advancing cell and gene therapies through integrated drug development services. The company offers preclinical testing, manufacturing, and analytics in a 200,000-square-foot facility. AmplifyBio supports therapies targeting oncology, rare diseases, and neurology. Launched in 2021 by former Battelle executives, it accelerates candidates from discovery to IND submission.

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

Loyal is a biotechnology firm developing small-molecule drugs to extend healthy lifespan in dogs by targeting aging pathways like insulin signaling. Headquartered in San Francisco, California, the company founded in 2020 conducts clinical trials for LOY-001, an oral tablet aimed at large-breed dogs over seven years old. Loyal collaborates with veterinary clinics nationwide and plans FDA submission in 2024. Its pipeline includes therapies for kidney disease and heart conditions linked to canine aging processes.

Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.